MA29890B1 - Composition a base d'herbes pour les troubles inflammatoires - Google Patents
Composition a base d'herbes pour les troubles inflammatoiresInfo
- Publication number
- MA29890B1 MA29890B1 MA30886A MA30886A MA29890B1 MA 29890 B1 MA29890 B1 MA 29890B1 MA 30886 A MA30886 A MA 30886A MA 30886 A MA30886 A MA 30886A MA 29890 B1 MA29890 B1 MA 29890B1
- Authority
- MA
- Morocco
- Prior art keywords
- compound
- compositions
- relates
- naphtho
- octahydro
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 abstract 2
- 244000085223 Sphaeranthus indicus Species 0.000 abstract 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 2
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 2
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 2
- 229940125904 compound 1 Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 2
- XMPDAVDYIOMTLX-UHFFFAOYSA-N 3a-Hydroxy-5a,9-dimethyl-3-methylidene-4,5,6,7,8,9b-hexahydrobenzo[g][1]benzofuran-2-one Chemical compound C1CC2(C)CCCC(C)=C2C2OC(=O)C(=C)C21O XMPDAVDYIOMTLX-UHFFFAOYSA-N 0.000 abstract 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 abstract 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 abstract 1
- 108010002352 Interleukin-1 Proteins 0.000 abstract 1
- 108090001005 Interleukin-6 Proteins 0.000 abstract 1
- 108090001007 Interleukin-8 Proteins 0.000 abstract 1
- 108010063738 Interleukins Proteins 0.000 abstract 1
- 102000015696 Interleukins Human genes 0.000 abstract 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 abstract 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000000975 bioactive effect Effects 0.000 abstract 1
- RHDGNLCLDBVESU-UHFFFAOYSA-N but-3-en-4-olide Chemical compound O=C1CC=CO1 RHDGNLCLDBVESU-UHFFFAOYSA-N 0.000 abstract 1
- 230000021164 cell adhesion Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000005732 intercellular adhesion Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 210000005167 vascular cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Botany (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
Abstract
L'INVENTION CONCERNE UNE COMPOSITION MÉDICINALE COMPRENANT UN EXTRAIT DE FLEUR ET DE FRUIT DE LA PLANTE SPHAERANTHUS INDICUS. L'EXTRAIT DE SPHAERANTHUS INDICUS RENFERME UN COMPOSÉ, 3A-HYDROXY-5A,9-DIMÉTHYL-3- MÉTHYLENE-3A,4,5,5A,6,7,8,9B-OCTAHYDRO-3H-NAPHTHO[1,2-B]FURAN-2-ONE (7- HYDROXY-4,1 1 (13)-EUDESMADIEN-12,6-OLIDE) (COMPOSÉ 1 ) EN TANT QUE MARQUEUR BIOACTIF. L'INVENTION CONCERNE ÉGALEMENT UNE COMPOSITION COMPRENANT 3A-HYDROXY-5A,9-DIMÉTHYL- 3-MÉTHYLENE-3A,4,5,5A,6,7,8,9B-OCTAHYDRO-3H-NAPHTHO[1,2-B]FURAN-2-ONE (COMPOSÉ 1 ) COMME INGRÉDIENT ACTIF. DE PLUS, L'INVENTION ENGLOBE DES MÉTHODES DE FABRICATION DESDITES COMPOSITIONS ET DES MÉTHODES D'ADMINISTRATION À U N SUJET DEVANT ÊTRE TRAITÉ POUR DES TROUBLES INFLAMMATOIRES. L'INVENTION PORTE ÉGALEMENT SUR L'ACTIVITÉ INHIBITRICE DE CES COMPOSITIONS À L'ÉGARD DU FACTEUR $G(A) DE NÉCROSE DES TUMEURS (TNF- A) ET DE L'INTERLEUKINE (IL-1, IL-6, IL-8). ELLE CONCERNE EN OUTRE L'INHIBITION PAR LESDITS COMPOSITIONS DE L'EXPRESSION DE LA MOLÉCULE 1 D'ADHÉSION INTERCELLULAIRE (ICAM-1 ), DE LA MOLÉCULE 1 D'ADHÉSION DES CELLULES VASCULAIRES (VCAM-1 ) ET DE LA SÉLECTINE E. CES COMPOSTIONS PEUVENT ÉVENTUELLEMENT CONTENIR AU MOINS UN AGENT ANTI-INFLAMMATOIRE OU PEUVENT ÊTRE UTILISÉES EN ASSOCIATION AVEC AU MOINS UN AGENT ANTI-INFLAMMATOIRE.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1226MU2005 | 2005-09-30 | ||
| US73644305P | 2005-11-14 | 2005-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA29890B1 true MA29890B1 (fr) | 2008-10-03 |
Family
ID=37900158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA30886A MA29890B1 (fr) | 2005-09-30 | 2008-04-29 | Composition a base d'herbes pour les troubles inflammatoires |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7635494B2 (fr) |
| EP (1) | EP1931366B1 (fr) |
| JP (1) | JP5331962B2 (fr) |
| AU (1) | AU2006296197B2 (fr) |
| CA (1) | CA2624049C (fr) |
| EA (1) | EA014070B1 (fr) |
| GE (1) | GEP20115332B (fr) |
| MA (1) | MA29890B1 (fr) |
| PL (1) | PL1931366T3 (fr) |
| WO (1) | WO2007036900A2 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200908958A (en) * | 2007-07-27 | 2009-03-01 | Piramal Life Sciences Ltd | Tricyclic compounds for the treatment of inflammatory disorders |
| US8383166B2 (en) * | 2007-12-03 | 2013-02-26 | Sequent Scientific Limited | Stable hydrophobic topical herbal formulationn |
| WO2012014216A1 (fr) * | 2010-07-28 | 2012-02-02 | Laila Nutraceuticals | 7-hydroxyfrullanolide et ses analogues pour la prévention, la maîtrise et le traitement de troubles du métabolisme. |
| US10105347B2 (en) | 2009-02-02 | 2018-10-23 | Laila Nutraceuticals | Sphaeranthus indicus derived ingredients and their compositions for enhancing physical performance and energy levels |
| WO2010100653A2 (fr) * | 2009-02-02 | 2010-09-10 | Laila Nutraceuticals | Composition provenant de sphaeranthus indicus et de garcinia mangostana pour maîtriser le syndrome métabolique |
| WO2011033524A2 (fr) * | 2009-08-04 | 2011-03-24 | Laila Nutraceuticals | Agents dérivés de ficus hispida pour l'amélioration du syndrome métabolique et de maladies associées |
| WO2011083397A1 (fr) * | 2010-01-05 | 2011-07-14 | Himalaya Global Holdings Limited | Composition phytothérapeutique pour les troubles de la peau |
| PH12013500451A1 (en) * | 2010-09-11 | 2013-05-20 | Laila Nutraceuticals | Sphaeranthus indicus derived ingredients and their compositions for enhancing physical performance and energy levels |
| US8263579B2 (en) * | 2011-01-24 | 2012-09-11 | Piramal Healthcare Limited | Anti-inflammatory compounds |
| CN104853761A (zh) * | 2012-10-23 | 2015-08-19 | 皮拉马尔企业有限公司 | 用于预防及治疗由肿瘤坏死因子-α介导的疾病的中药组合物 |
| AU2016281656B2 (en) | 2015-06-23 | 2019-05-30 | Nobilis Therapeutics, Inc. | Therapeutic immune modulation using noble gas compositions |
| WO2017203540A1 (fr) * | 2016-05-21 | 2017-11-30 | Laila Impex | Compléments alimentaires et compositions permettant d'améliorer les performances physiques et les niveaux d'énergie |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5646687A (en) * | 1994-12-29 | 1997-07-08 | Lucent Technologies Inc. | Temporally-pipelined predictive encoder/decoder circuit and method |
| US6204523B1 (en) * | 1998-11-06 | 2001-03-20 | Lumileds Lighting, U.S., Llc | High stability optical encapsulation and packaging for light-emitting diodes in the green, blue, and near UV range |
| US6686676B2 (en) * | 2001-04-30 | 2004-02-03 | General Electric Company | UV reflectors and UV-based light sources having reduced UV radiation leakage incorporating the same |
| US6989412B2 (en) * | 2001-06-06 | 2006-01-24 | Henkel Corporation | Epoxy molding compounds containing phosphor and process for preparing such compositions |
| US6841647B2 (en) * | 2001-11-06 | 2005-01-11 | National Starch And Chemical Investment Holding Corporation | Fluid resistant silicone encapsulant |
| US7160972B2 (en) * | 2003-02-19 | 2007-01-09 | Nusil Technology Llc | Optically clear high temperature resistant silicone polymers of high refractive index |
| US7261441B2 (en) * | 2004-02-27 | 2007-08-28 | Avago Technologies Ecbu Ip (Singapore) Pte. Ltd. | LED device and method for directing LED light |
| WO2006016228A2 (fr) * | 2004-08-02 | 2006-02-16 | Prashanth Kumar V | Alkaloide peptide cytotoxique et compositions pharmaceutiques pour le traitement des maladies neoplastiques |
| US7229934B2 (en) * | 2004-10-18 | 2007-06-12 | International Business Machines Corporation | Porous organosilicates with improved mechanical properties |
-
2006
- 2006-09-28 EP EP06809434.1A patent/EP1931366B1/fr active Active
- 2006-09-28 EA EA200800850A patent/EA014070B1/ru active IP Right Revival
- 2006-09-28 WO PCT/IB2006/053540 patent/WO2007036900A2/fr not_active Ceased
- 2006-09-28 JP JP2008532961A patent/JP5331962B2/ja not_active Expired - Fee Related
- 2006-09-28 AU AU2006296197A patent/AU2006296197B2/en not_active Ceased
- 2006-09-28 PL PL06809434T patent/PL1931366T3/pl unknown
- 2006-09-28 CA CA2624049A patent/CA2624049C/fr active Active
- 2006-09-28 GE GEAP200610647A patent/GEP20115332B/en unknown
-
2008
- 2008-03-28 US US12/079,853 patent/US7635494B2/en active Active
- 2008-04-29 MA MA30886A patent/MA29890B1/fr unknown
-
2009
- 2009-07-09 US US12/500,057 patent/US8206756B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2624049A1 (fr) | 2007-04-05 |
| EP1931366B1 (fr) | 2013-05-29 |
| JP2009510051A (ja) | 2009-03-12 |
| EA014070B1 (ru) | 2010-08-30 |
| CA2624049C (fr) | 2016-01-12 |
| AU2006296197B2 (en) | 2012-08-09 |
| US8206756B2 (en) | 2012-06-26 |
| GEP20115332B (en) | 2011-11-25 |
| US20090269427A1 (en) | 2009-10-29 |
| PL1931366T3 (pl) | 2013-11-29 |
| HK1112418A1 (en) | 2008-09-05 |
| AU2006296197A2 (en) | 2008-06-05 |
| US20080254157A1 (en) | 2008-10-16 |
| AU2006296197A1 (en) | 2007-04-05 |
| WO2007036900A2 (fr) | 2007-04-05 |
| EA200800850A1 (ru) | 2008-10-30 |
| JP5331962B2 (ja) | 2013-10-30 |
| EP1931366A2 (fr) | 2008-06-18 |
| US7635494B2 (en) | 2009-12-22 |
| WO2007036900A3 (fr) | 2007-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA29890B1 (fr) | Composition a base d'herbes pour les troubles inflammatoires | |
| MA30342B1 (fr) | Nouvelles compositions pour des troubles capillaires et procede de preparation de celles-ci | |
| NL350084I2 (nl) | Sedaxaan en Fludioxonil | |
| ATE459357T1 (de) | Kombinationen zur behandlung von multiplem myelom | |
| WO2005000241A8 (fr) | Compositions et procedes pour administration topique | |
| MA27125A1 (fr) | Composes de thienodibenzoazulene comme inhibiteurs de facteurs de tumeur de necrose | |
| WO2006119389A3 (fr) | Preparations de quinine | |
| Aggarwal et al. | Ocimum tenuiflorum-a medicinal plants with its versatile uses | |
| Hakobjanyan et al. | Medicinal potential of Thuja occidentalis and its essential oil | |
| CO5280139A1 (es) | Procedimiento para obtener plantas con un mayor contenido de flavonoides y compuestos fenolicos | |
| WO2023069514A3 (fr) | Composés bifonctionnels pour la dégradation de l'itk par l'intermédiaire d'une voie de l'ubiquitine protéosome | |
| Sheneni et al. | Anti-hyperlipidemic effect of Vitex doniana ethanol extract in poloxamer induced hyperlipidemia | |
| CA2441826A1 (fr) | Compositions fongicides a base de derive de pyridylmethylbenzamide et de propamocarbe | |
| ES2426174T8 (es) | Composición herbácea para trastornos inflamatorios | |
| Rajah et al. | Potential Malaysian medicinal plants for the treatment of Alzheimer’s disease | |
| Venugopal et al. | Cocos Nucifera: It’s pharmacological activities | |
| AR037334A1 (es) | Composicion fungicida que comprende pirimetanil y al menos un derivado de acido fosforoso y utilizacion de esta composicion para la lucha contra las enfermedades de las plantas | |
| WO2005112914A3 (fr) | Antioxydants phénoliques pour le traitement de troubles incluant l’arthrite, l’asthme et les troubles des artères coronaires | |
| Mohamed et al. | Promising selective MAO-B inhibition by sesamin, a lignan from Zanthoxylum flavum stems | |
| Nagarajan et al. | Queen of herb-Ocimum sanctum Linn (Tulsi) and its medicinal importance–A review | |
| BR0016451B1 (pt) | mÉtodo de desfolhar plantas de safra e minimizar o recrescimento seguinte À desfolhaÇço, e, composiÇço vegetal para desfolhar plantas de safra e minimizar o recrescimento da planta. | |
| Bhattacharya et al. | In vitro regeneration of some lesser known medicinal Zingibers: a review | |
| Mohebbati et al. | Hypotensive effect of hydroalcoholic Ziziphus jujuba extract on normotensive rats | |
| WO2007014379A3 (fr) | Extrait lipidique provenant de lepidium meynii et effet de celui-ci sur la libido | |
| Isla et al. | Fabiana punensis SC Arroyo, F. bryoides Phil., F. densa Remy, F. patagonica Speg. |